Acoramidis
AG10-334
Phase 3 small_molecule terminated
Quick answer
Acoramidis for Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy is a Phase 3 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated